New treatments/targets for primary biliary cholangitis.

ABSTRACT: Primary biliary cholangitis (PBC) is an autoimmune, cholestatic, chronic liver disease that ultimately progresses towards cirrhosis and liver failure if untreated. While ursodeoxycholic acid has been established as standard of care for PBC in the last few decades, significant advances in second-line treatment options have recently been made and new therapeutic developments are currently under evaluation. The purpose of this article is to provide the clinician with an overview of the current treatment options and future opportunities for patients with PBC.

SUBMITTER: Corpechot C 

PROVIDER: S-EPMC7001536 | biostudies-literature | 2019 Sep

REPOSITORIES: biostudies-literature